Dr. Stephen (Steven) Klein

speaker

467 appearances 1 recordings 1 series first heard Jul 2026 last heard 2 Jul

Dr. Stephen (Steven) Klein’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 1 in all, peaking in Jul 2026 with 1.

newest first · ▶ plays the moment

Now, companies make peptides.

So semaglutide, the active ingredient in Ozempic and Wegovy, is a peptide that really Nova Nordisk controls.

Zetbound, Monjorno is a much bigger peptide, more spaghetti, a couple more meatballs, and that's controlled by Eli Lilly.

Those are blockbusters for weight loss.

For example, the valuation of Nova Nordisk, a Danish company, just exceeded the GDP of the country of Denmark.

These are big money makers.

Wow.

So they are very protective of these peptides.

They're very protective of what they're used for, what they're not.

When I say another company is going to bring a peptide, they're just going to make a different combination of spaghetti and meatballs.

And their indication, what they're trying to treat is alcohol use disorder.

Okay.

So they're potentially the same mechanisms.

They may have a little bit of difference.

They may be a little bit different in size or where they bind or their ability to get into the brain or different regions of the brain.

But the fact that companies are focusing just on that really highlights that there's an unmet need.

Right now, my personal practice and my practice at care and treatment centers is that we are at that moment.

We are in the present of GLP-1s.

I think there is a wave coming.

We're kind of in the tidal wave of that – we're in the tidal pool of that tidal wave, if you will –

Showing 421–440 of 467 · page 22 of 24